

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

Zexi Hu^{1,2,*}, Yong Hu^{1,2,*}, Xicheng Liu², Rongwen Xi², Aiqun Zhang³, Deruo Liu⁴, Qiang Xie⁵ and Liang Chen^{2,6}

¹ College of Life Sciences, Beijing Normal University, Beijing, China

² National Institute of Biological Sciences, Beijing, China

³ The General Hospital of People's Liberation Army (301 hospital), Beijing, China

⁴ Department of thoracic surgery, China-Japan Friendship Hospital, Beijing, China

⁵ Fuzhou Pulmonary Hospital of Fujian, Fujian, China

⁶ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China

* Co-first author

Published: October 16, 2018

Copyright: Hu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The correct Acknowledgment information is given below:

ACKNOWLEDGMENTS

This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 2015; 6:31628-31639. <https://doi.org/10.18632/oncotarget.5221>